Dual Inhibition in the Management of Moderate to Severe Asthma: Selecting the Appropriate Biologic Therapy Based on Individualized Factors

This activity includes patient counseling video vignettes.

Program Description

For patients whose asthma is uncontrolled with traditional medications and who experience exacerbations and hospitalizations, biologic therapies have offered substantial improvements in quality of life. As additional therapies emerge, pharmacists require a deeper grasp of the disease to tailor these medications to each patient's specific needs. This session will focus on the significant burden and unmet needs in the management of moderate to severe asthma and the role of biologic therapy. Patient case video vignettes will be utilized to highlight the role of the specialty pharmacist in asthma care, including patient education and opportunities to assist the multidisciplinary team in the appropriate selection of biologic therapy based on individual patient factors for therapy initiation and optimization.

Target audience: Specialty pharmacists, retail pharmacists, and health-system pharmacists

Type of activity: Application
Release date: July 24, 2024
Expiration date: July 24, 2025

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the substantial burden of uncontrolled symptoms and exacerbations for patients with moderate to severe asthma
• Analyze safety and efficacy data for approved biologic therapies for the management of moderate to severe asthma
• Identify opportunities for pharmacist-led counseling of patients and caregivers on use of biologic therapies in the management of moderate to severe asthma

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-24-226-H01-P. The activity is available for CE credit through July 24, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Elizabeth Autry, PharmD, BCPPS

Shannon M. Rotolo, PharmD, BCPS

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms